e-Article
The CALHM1 P86L Polymorphism is a Genetic Modifier of Age at Onset in Alzheimer's Disease: a Meta-Analysis Study.
Document Type
Article
Author
Lambert, Jean-Charles; Sleegers, Kristel; González-Pérez, Antonio; Ingelsson, Martin; Beecham, Gary W.; Hiltunen, Mikko; Combarros, Onofre; Bullido, Maria J.; Brouwers, Nathalie; Bettens, Karolien; Berr, Claudine; Pasquier, Florence; Richard, Florence; DeKosky, Steven T.; Hannequin, Didier; Haines, Jonathan L.; Tognoni, Gloria; Fiévet, Nathalie; Dartigues, Jean-François; Tzourio, Christophe
Source
Subject
*AGE of onset
*ALZHEIMER'S disease
*APOLIPOPROTEIN E
*GENETIC polymorphisms
*HOMEOSTASIS
*GENES
*
*
*
*
*
Language
ISSN
1387-2877
Abstract
The only established genetic determinant of non-Mendelian forms of Alzheimer's disease (AD) is the ℇ4 allele of the apolipoprotein E gene (APOE). Recently, it has been reported that the P86L polymorphism of the calcium homeostasis modulator 1 gene (CALHM1) is associated with the risk of developing AD. In order to independently assess this association, we performed a meta-analysis of 7,873 AD cases and 13,274 controls of Caucasian origin (from a total of 24 centers in Belgium, Finland, France, Italy, Spain, Sweden, the UK, and the USA). Our results indicate that the CALHM1 P86L polymorphism is likely not a genetic determinant of AD but may modulate age of onset by interacting with the effect of the ℇ4 allele of the APOE gene. [ABSTRACT FROM AUTHOR]